Treats clinically important hypotension occurring in the setting of anesthesia. ANDA 217721, held by Hikma. Ephedrine Sulfate.
As of Nov 16, 2026, ANDA 217721 (Ephedrine Sulfate), held by Hikma, was first approved by FDA on Oct 11, 2024, with 0 approved supplements and 0 published complete response letters.
Ephedrine Sulfate Injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 11, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ephedrine Sulfate25MG/5ML (5MG/ML) · solution;intravenous | Ephedrine Sulfate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters